Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia

Pharmacotherapy

Volumn 16, Issue 6 I, 1996, Pages 1030-1038

  Warnock, Allison C ^a   Rimland, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; COTRIMOXAZOLE; DAPSONE; DIDANOSINE; PENTAMIDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INHALATIONAL DRUG ADMINISTRATION; LUNG LAVAGE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS PNEUMONIA; TOXOPLASMOSIS;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTI-INFECTIVE AGENTS; DAPSONE; FEMALE; HUMANS; MALE; MIDDLE AGED; PENTAMIDINE; PNEUMOCYSTIS; PNEUMONIA, PNEUMOCYSTIS; RETROSPECTIVE STUDIES; TOXOPLASMA; TOXOPLASMOSIS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0029828810     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Centers for Disease Control. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR 1992;41(RR-4):1-11.
2. Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with the human immunodeficiency virus. MMWR 1989;38(S-5):1-9.
3. Montgomery AB. Pneumocystis carinii pneumonia prophylaxis: past, present and future. AIDS 1992;6:227-8.
4. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;327(26):1842-8.
5. Carr A, Tindall B, Penny R, Cooper DA. Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS. AIDS 1992;6:165-71.
6. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332(11):693-9.
7. Schneider MME, Hoepelman AIM, Eeftinck Schattenkerk JKM, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992;327:1836-41.
8. Podzamczer D, Santin M, Jimenaz J, Casanova A, Balae F, Gudiol GRF. Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients. AIDS 1993;7:501-6.
9. Podzamczer D, Salazar A, Jimenez J, et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med 1995;122:755-61.
10. Chaisson RE, Keruly J, Richman DD, Moore RD. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. Arch Intern Med 1992;152:2009-13.
11. Mallolas J, Zamora L, Gatell JM, et al. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine. AIDS 1993;7:59-64.
12. Martin MA, Cox PH, Beck K, Styer CM, Beall GN. A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Arch Intern Med 1992;152:523-8.
13. Blum RN, Miller LA, Gaggini LC, Cohn DL. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. J Acquir Immun Defic Syndr 1992;5:341-7.
14. Metroka CE, McMechan MF, Andrada R. Failure of prophylaxis with dapsone in patients taking dideoxyinosine [letter]. N Engl J Med 1991;325:737.
15. Sahai J, Garber G, Gallicano K, Oliveras L, Cameron DW. Effects of the antacids in didanosine tablets on dapsone pharmacokinetics. Ann Intern Med 1995;123:584-7.
16. Breen GA, Brocavich JM, Etzel JV, Shav V, Schaefer P, Forlenza S. Evaluation of effects of altered gastric pH on absorption of dapsone in healthy volunteers. Antimicrob Agents Chemother 1994;38:2227-9.
17. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988;259:1185-9.
18. Jorde UP, Horowitz HW, Wormser GP. Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole-intolerant, HIV-infected individuals. AIDS 1993;7:355-9.
19. Jensen BN, Neilsen TL, Backer V, et al. Aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a controlled, randomized trial. J Acquir Immun Defic Syndr 1993;6:472-7.
20. Pretet S, Salmon D, Rousseau F, et al. Long-term results of monthly inhaled pentamidine as primary prophylaxis of Pneumocystis carinii pneumonia in HIV-infected patients. Am J Med 1993;94:35-40.
21. Hirschel B, Lazzarin A, Chopard P, et al. A controlled trial of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med 1991;324:1079-83.
22. Northfelt DW, Clement MJ, Safrin S. Extrapulmonary pneumocystosis: clinical features of human immunodeficiency virus infection. Medicine 1990;69:392-8.
23. Slavin MA, Hoy JF, Stewart K, Pettinger MB, Lucas CR, Kent SJ. Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity. AIDS 1992;6:1169-74.
24. Pertel P, Hirschtick R. Adverse reactions to dapsone in persons infected with human immunodeficiency virus. Clin Infect Dis 1994;18(4):630-2.
25. Centers for Disease Control and Prevention. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR 1995;44:24.